{"id":"7b3728d3f596","type":"article","url":"https://hartvaat.nl/2019/05/28/dapagliflozine-en-hartfalen-en-mortaliteit-bij-diabetes-type-2-declare-timi-58-h/","title":"Dapagliflozine en hartfalen en mortaliteit bij diabetes type 2: DECLARE-TIMI 58 HF-analyse","title_en":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapa-hf","dapagliflozine","empagliflozine"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.119.040130","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.119.040130","authors":["Eri T Kato","Michael G Silverman","Ofri Mosenzon","Thomas A Zelniker","Avivit Cahn","Remo H M Furtado","Julia Kuder","Sabina A Murphy","Deepak L Bhatt","Lawrence A Leiter","Darren K McGuire","John P H Wilding","Marc P Bonaca","Christian T Ruff","Akshay S Desai","Shinya Goto","Peter A Johansson","Ingrid Gause-Nilsson","Per Johanson","Anna Maria Langkilde","Itamar Raz","Marc S Sabatine","Stephen D Wiviott"],"significance":8,"published":"2019-05-28","source_date":"2019-05-28","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This DECLARE-TIMI 58 heart failure analysis confirmed that dapagliflozin significantly reduces heart failure hospitalization and cardiovascular death in patients with type 2 diabetes, with the greatest benefit in those with prior heart failure. The results strengthened the heart failure prevention role of SGLT2 inhibitors.","created":"2026-07-03T10:27:56Z","updated":"2026-07-03T13:27:09Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"DECLARE-TIMI 58 analyse specifiek naar het effect van dapagliflozine op hartfalen en mortaliteit bij diabetes type 2. Bevestigt het HF-preventieve effect.","abstract_original":"BACKGROUND: In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition is unknown. METHODS: In the DECLARE-TIMI 58 trial, baseline heart failure (HF) status was collected from all patients, and EF was collected when available. HF with reduced EF (HFrEF) was defined as EF <45%. Outcomes of interest were the composite of cardiovascular death/HHF, its components, and all-cause mortality. RESULTS: Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 (7.7%) had HF without known reduced EF, and 15 173 (88.4%) had no history of HF at baseline. Dapagliflozin reduced cardiovascular death/HHF more in patients with HFrEF (hazard ratio [HR], 0.62 [95% CI, 0.45-0.86]) than in those without HFrEF (HR, 0.88 [95% CI, 0.76-1.02]; P for interaction=0.046), in whom the treatment effect of dapagliflozin was similar in those with HF without known reduced EF (HR, 0.88 [95% CI, 0.66-1.17]) and those without HF (HR, 0.88 [95% CI, 0.74-1.03]). Whereas dapagliflozin reduced HHF both in those with (HR, 0.64 [95% CI, 0.43-0.95]) and in those without HFrEF (HR, 0.76 [95% CI, 0.62-0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, 0.55 [95% CI, 0.34-0.90]) but not in those without HFrEF (HR, 1.08 [95% CI, 0.89-1.31]; P for interaction=0.012). Likewise, dapagliflozin reduced all-cause mortality in patients with HFrEF (HR, 0.59 [95% CI, 0.40-0.88;) but not in those without HFrEF (HR, 0.97 [95% CI, 0.86-1.10]; P for interaction=0.016). CONCLUSIONS: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, we found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in patients with HFrEF. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01730534."}